In the News
As reported by Bio.com, June 12, 2007.
NIH Awards Nearly $21 Million to Fund
Cutting-Edge Research Equipment
The National Center for Research Resources (NCRR),
a part of the National Institutes of Health (NIH), announced today
it will provide $20.65 million for 14 High-End Instrumentation (HEI)
grants that will fund cutting-edge equipment required to advance
biomedical research. Awarded to research institutions around the
country, the one-time grants support the purchase of sophisticated
instruments costing more than $750,000.
“These high-performance imaging instruments and other advanced
technologies enable both basic discoveries that shed light on the
underlying causes of disease and the development of novel therapies
to treat them,” said Barbara Alving, M.D., NCRR Director. “The value
of this investment in advanced equipment is greatly leveraged
because each of these rare tools is used by a number of
investigators, advancing a broad range of research projects.”
The 14 awards in this round of funding will enable the purchase
of a variety of sophisticated instrumentation at institutions
nationwide. For example, Nashville’s Vanderbilt University will
acquire a 7 Tesla human magnetic resonance imaging (MRI) and
spectroscopy system, which provides the highest magnetic imaging
available for humans and is one of only several such instruments in
the country. With its award, the University of Texas Health Sciences
Center in San Antonio will obtain a high-field 7 Tesla MRI scanner
capable of performing such demanding studies as functional brain and
cardiac imaging in a variety of animal species.
Meanwhile, the purchase of several 3 Tesla MRI scanners will be
used to develop minimally invasive therapies at Brigham and Women’s
Hospital in Boston; and for psychiatric applications at the Nathan
S. Kline Institute for Psychiatric Research in Orangeburg, N.Y. In
addition, nuclear magnetic resonance spectrometers will be supported
to probe intermolecular interactions at Burnham Institute for
Medical Research in La Jolla, Calif.; and to research protein
structure, function, and folding at the University of Connecticut
School of Medicine and Dentistry in Farmington. Three
high-performance, hybrid linear ion trap-Fourier transform mass
spectrometers will be funded. One will be located at Johns Hopkins
University in Baltimore, Md., to benefit researchers investigating
ischemia and hypoxia, among other projects; another at the
University of Arizona at Tucson will enable structural studies of
proteins; and the third at the University of Colorado at Denver and
Health Sciences Center will facilitate cancer research and other
studies. Also, a pulsed electron paramagnetic resonance/X-band
electron nuclear double resonance spectrometer will be purchased by
the University of Washington in Seattle, to study the function of
enzymes, structural proteins, and proteins at DNA and RNA
interfaces.
Another award will support the University of California, San
Diego, in its purchase of a high-performance, intermediate voltage
transmission electron microscope to enable 3-D imaging of sections
of cells and biological tissues. Also funded is a confocal imaging
system at the University of Maryland Biotechnology Institute in
Baltimore, to enable the study of calcium signaling in living cells,
as well as investigations involving neuronal and brain slice
imaging.
At the University of Wisconsin School of Medicine and Public
Health in Madison, positron emission tomography tracer development
and production equipment will be purchased to facilitate research
involving cancer, neuroscience, cardiovascular, and regenerative
medicine. Finally, new state-of-the-art DNA sequencing
instrumentation will be acquired by Yale University in New Haven,
Conn., to assist investigations involving epilepsy, psychiatric
disorders, autism, cardiovascular disorders, and cancer.
For more details on the High-End Awards, please visit:
http://www.ncrr.nih.gov/biomedical_technology/high-end_instrumentation/hei_awards_12june2007.asp.
In order to qualify for a HEI award, institutions must identify
three or more NIH-funded investigators whose research requires the
requested instrument. Matching funds are not required for these
grants, which provide a maximum of $2 million each. However,
institutions are expected to provide an appropriate level of support
for associated infrastructure, such as building alterations or
renovations, technical personnel, and post-award service contracts
for instrument maintenance and operation.
More information about the High-End Instrumentation program,
including application guidelines, is available at:
http://www.ncrr.nih.gov/biomedical_5Ftechnology/high_2Dend_5Finstrumentation/.
NCRR provides laboratory scientists and clinical researchers with
the environments and tools they need to understand, detect, treat,
and prevent a wide range of diseases. Central to this effort, NCRR
leads the Clinical and Translational Science Award (CTSA) program —
a national consortium of academic health centers that will transform
the conduct of clinical and translational research to ensure that
biomedical discoveries are rapidly translated into prevention
strategies and clinical treatments for rare and common diseases.
With NCRR support, scientists make biomedical discoveries, translate
these findings to animal-based studies, and then apply them to
patient-oriented research. Through the CTSA consortium and other
collaborations and networks, NCRR connects researchers with one
another, and with patients and communities across the nation. These
connections bring together innovative research teams and the power
of shared resources, multiplying the opportunities to improve human
health. For more information, visit
www.ncrr.nih.gov.
The National Institutes of Health (NIH) — The Nation's Medical
Research Agency — includes 27 Institutes and Centers and is a
component of the U.S. Department of Health and Human Services. It is
the primary federal agency for conducting and supporting basic,
clinical and translational medical research, and it investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit
www.nih.gov. |